A lung adenocarcinoma patient with EGFR mutation in exon 18 and ALK-rearrangement who treated with erlotinib and crizotinib
Concomitant mutations of echinoderm microtubule-associated protein-like 4 (EML4) anaplastic lymphoma kinase (ALK) translocation and epidermal growth factor receptor (EGFR) can be found rarely in lung adenocarcinoma. We present a case of harboring EML4/ALK rearrangement lung adenocarcinoma who previo...
Saved in:
Main Authors: | Mehmet Artaç, Levent Korkmaz, Mustafa Karaağaç, Buğra Kaya, Necdet Poyraz, Hakan Özön, Zehra Er, Lema Tavlı |
---|---|
Format: | Article |
Language: | English |
Published: |
Galenos Publishing House
2018-08-01
|
Series: | Journal of Oncological Sciences |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2452336417301085 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
EFFICACY OF TARGET THERAPY WITH CRIZOTINIB IN A PATIENT WITH ALK-POSITIVE ADVANCED GASTRIC CANCER
by: A. A. Paichadze, et al.
Published: (2020-03-01) -
Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
by: Naoko Imanishi, et al.
Published: (2018-03-01) -
CLINICAL EFFICACY OF TARGETED THERAPY TOWARDS METASTATIC LUNG CANCER CARRYING DISTINCT TYPES OF ALK REARRANGEMENTS
by: N. V. Mitiushkina, et al.
Published: (2020-09-01) -
Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
by: Wenhua Liang, et al.
Published: (2014-01-01) -
Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis.
by: Liang Fan, et al.
Published: (2014-01-01)